EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation

Source Summary

GLASGOW, Scotland, July 07, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company developing orally delivered full-spectrum microbiome therapeutics for gastrointestinal disease, today announced that the first patient has been dosed in RISE, its Phase 2b clinical trial evaluating EBX-102-02 in moderate-to-severe irritable bowel syndrome with constipation (IBS-C), marking an important milestone in the Company’s clinical development programme.